share_log

华海药业(600521.SH):奥美沙坦酯氨氯地平片获得药品注册证书

Zhejiang Huahai Pharmaceutical (600521.SH): The drug registration certificate for amlodipine and olmesartan medoxomil tablets has been obtained.

Gelonghui Finance ·  Jul 5 05:22

On July 5th, Gelunhui reported that Zhejiang Huahai Pharmaceutical (600521.SH) recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of the registration of the combination of Olmesartan Medoxomil and Amlodipine besylate tablets, which is used for the treatment of primary hypertension.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment